A Study of Two Doses of 18F-AV-45 in Alzheimer's Disease and Healthy Volunteers

Exclusion Criteria

• •Neurodegenerative disorders other than AD, including, but not limited to Parkinson's disease, Pick's disease, fronto-temporal dementia, Huntington's chorea, Down syndrome, Creutzfeldt-Jacob disease, normal pressure hydrocephalus, and progressive supranuclear palsy
• •Diagnosis of other dementing / neurodegenerative disease
• •Diagnosis of mixed dementia
• •Cognitive impairment resulting from trauma, hypoxic damage, vitamin deficiency, brain infection, brain cancer, endocrine disease, or mental retardation
• •Clinically significant infarct or possible multi-infarct dementia as defined by the NINCDS criteria
• •Evidence on screening MRI or other biomarker that suggests alternate etiology for cognitive deficit (for healthy controls, evidence suggesting the presence of AD pathology)
• •Clinically significant psychiatric disease
• •History of epilepsy or convulsions
• •Clinically significant hepatic, renal, pulmonary, metabolic, or endocrine disturbances
• •Current clinically significant cardiovascular disease
• •Received investigational medication within the last 30 days